Clenbuterol, wani β2-adrenergic agonist ne (β2-adrenergic agonist), kamar ephedrine (Ephedrine), ana amfani da shi a asibiti don magance cututtukan huhu na yau da kullun (COPD). Haka kuma ana amfani da shi azaman bronchodilator don rage yawan asma mai tsanani. A farkon shekarun 1980, kamfanin Amurka Cyanamid ya gano ba zato ba tsammani cewa yana da tasirin inganta girma, inganta yawan nama mai laushi da rage kitse, don haka an yi amfani da shi azaman clenbuterol a kiwon dabbobi. Duk da haka, saboda illolinsa, Ƙungiyar Turai ta haramta amfani da clenbuterol a matsayin ƙarin abinci tun daga ranar 1 ga Janairu, 1988. Hukumar FDA ta hana shi a shekarar 1991. A shekarar 1997, Ma'aikatar Noma ta Jamhuriyar Jama'ar China ta haramta amfani da hormones na beta-adrenergic a cikin samar da abinci da kiwon dabbobi, kuma Clenbuterol hydrochloride ya kasance na farko.
Duk da haka, kwanan nan an nuna cewa Clenbuterol mai launin racemic yana rage haɗarin kamuwa da cutar Parkinson. Domin tabbatar da waɗanne isomers (ko duka biyun) ke samar da wannan tasirin, ana buƙatar yin nazarin Clenbuterol enantiomer daban.
A cikin wani labarin da aka buga kwanan nan, ƙungiyar bincike ta Elisabeth Egholm Jacobsen ta Sashen Kimiyyar Sinadarai, Jami'ar Kimiyya da Fasaha ta Norway, tare da haɗin gwiwar Dr. Zhu Wei na Shangke Bio, sun haɓaka haɗakar ketoreductase KRED da cofactor nicotinamide adenine dinucleoside phosphate (NADPH). (R)-1-(4-Amino-3,5-dichlorophenyl)-2-bromoethan-1-ol, ee > 93%; kuma (S)-N-(2) an haɗa shi ta hanyar tsarin iri ɗaya ,6-Dichloro-4-(1-hydroxyethyl)phenyl)acetamide, ee >98%. Duk waɗannan tsaka-tsakin da ke sama sune abubuwan da za su iya zama tushen isomers na clenbuterol. An buga sakamakon binciken "Chemoenzymatic Synthesis of Synthons as Precursors for Enantiopure Clenbuterol and Other -2-Agonists" a cikin "Catalysts" a ranar 4 ga Nuwamba, 2018.
Lokacin Saƙo: Agusta-26-2022